{"id":690226,"date":"2022-09-29T08:18:16","date_gmt":"2022-09-29T12:18:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/"},"modified":"2022-09-29T08:18:16","modified_gmt":"2022-09-29T12:18:16","slug":"sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/","title":{"rendered":"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:12pt;text-align:center\">\n          <em>GFH009 Formulation is Near Physiological pH, While Still Achieving Desired Effect &#8211;<\/em>\n        <\/li>\n<li style=\"margin-bottom:12pt;text-align:center\">\n          <em>GFH009 at pH 6.0 Decreased Potential for Infusion Reaction and Made Dosing Better Tolerated After Multiple Doses or Long-time Infusion &#8211;<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">NEW YORK, Sept.  29, 2022  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8wAKnYhhcVlE_7wVxyksh_24wePgkEFePQhL6hSj9MzBGziPQOyFOTjTRtEGMi1uhVYxmygKItzD4dNsBRHOwe-w3xmUI3ZpzNfZLUsye0MqX2JIGLCuwH9ZKVGT_ojx1CGeimtFPZY2rtMSYqxfZw==\" rel=\"nofollow noopener\" target=\"_blank\">SELLAS Life Sciences Group, Inc.<\/a> (NASDAQ: SLS) (\u201cSELLAS\u201d or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced today data from a bioequivalence study for GFH009, its potent, highly selective, clinical-stage small molecule that inhibits cyclin-dependent kinase 9 (CDK9). In the ongoing Phase 1 clinical trial of GFH009 monotherapy in patients with relapsed\/refractory hematologic conditions, including acute myeloid leukemia and lymphoma, GFH009 is administered intravenously as a solution. The bioequivalence study was performed to evaluate the effect of different formulations on GFH009\u2019s preclinical pharmacokinetic (PK) profile. Dr. Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS, presented the findings at this year\u2019s Meeting of the Society of Hematologic Oncology (SOHO) in a poster titled \u201cPharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague Dawley Rats.\u201d<\/p>\n<p align=\"justify\">The solution for GFH009 was originally developed with the pH of 4.5 (acidic). Human blood has a physiological pH of around 7.35 to 7.45. The closer a drug is to this physiological state, the less acidic and irritating it is for patients. In a four-week rat study, GFH009 was tested at 2.0 mg\/kg, 4.0 mg\/kg and 8.0 mg\/kg. At 4.0 mg\/kg, drug exposure approached efficacy, which formed the rationale for the dose selection for the presented PK study. Rats were randomly assigned to group one (pH 4.5) or group two (pH 6.0) and matched by sex and body weight. Each rat received a single dose of GFH009 (4.0 mg\/kg) at pH 4.5 or pH 6.0 intravenously in the tail vein at a volume of 5.0 mL\/kg. The PK profiles of both GFH009 formulations (pH 4.5 and pH 6.0) were found to be comparable, supporting the application of the pH 6.0 formulation in the ongoing Phase 1 clinical trial.<\/p>\n<p align=\"justify\">\u201cAt pH 6.0, GFH009 is closer to the physiological pH \u2013 thus, it is less acidic \u2013 and the drug\u2019s behavior remains comparable to that at pH 4.5,\u201d said Dr. Cicic. \u201cAs a result, this study allowed us to explore a range of dosing strategies for patients, which helped with dose preparation and administration. The improved formulation also decreased the potential for the infusion reaction and made dosing more well-tolerated after multiple doses or long-time infusion.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About SELLAS Life Sciences Group, Inc.<\/strong><br \/>\n        <br \/>SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS\u2019 lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.<\/p>\n<p>For more information on SELLAS, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qeRtLXUrQUQQ4klqlleBubVKYFKK2ffc2HQxPLz5h6XABo0fVsBWmBlmKrpf5KkNK8wZPu1YbODnnMnc6YZ2JkU3amLh9XuDk47NzPKoSVBXnOyB1G6_2v26lGlK90Fz\" rel=\"nofollow noopener\" target=\"_blank\">www.sellaslifesciences.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements. All statements other than statements of historical facts are \u201cforward-looking statements,\u201d including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as \u201cplan,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cintend,\u201d or \u201ccontinue\u201d and other words or terms of similar meaning. These statements include, without limitation, statements related to preclinical data for GFH009, plans for further development of GFH009, and the potential for GFH009 as a drug development candidate. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company\u2019s clinical plans and business strategy, risks and uncertainties associated with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption \u201cRisk Factors\u201d in SELLAS\u2019 Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS\u2019 forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Allison Soss <br \/>KCSA Strategic Communications <br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8wAKnYhhcVlE_7wVxykshxlbpm-5dMpR5xRLWpKyrtJePUKU8BFb0lzOi7HqT8SslIzpe4DA4z7ayDCCJLEYMg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>SELLAS@kcsa.com <\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GyczRtztiYKhVyTGo-wZcxGPXyY2Fypi6-tmSicjmdoXJO-xTBgOgvQ6q7EqM9oykxPRsBpOD1Yo8_dhL0PDoshLrsx2NYbcYX0f2QlvQ8h43rEiDgEuzaIz_SBVndvICPjXISMNZbP6lc87L4lilT2flDyP_tkxzFo_ls1XzWgd6-D-Sjl0Dua4io8cKCuvHcso1qRFPXZryjZA4B5fNw==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/><\/a>Phone: 212.896.1267<\/p>\n<p align=\"justify\">\n        <strong>Media Contacts<\/strong><br \/>\n        <br \/>Raquel Cona \/ Michaela Fawcett <br \/>KCSA Strategic Communications <br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8wAKnYhhcVlE_7wVxyksh5ZQ8gvySVyq1LdpjEYxcdXX7Bh_L7YQQq-uJWhSjBFqZr2ZNjXKhWE460sp93ROaQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>SELLAS@kcsa.com <\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_YMdgLatpcf4T9H_mTU0t6MIV2c7FbJnpvMEZnTjjqMWWTBIYdsOqC9HOokX35s518uMqNIOGjSA_zWAgh4Qd0xsEjBmNdrO67STOMe4CzUdk0n4Fredfcc01_auMbQrYL79pTaLBVz9kXrO_4CHZJXeCa_-MmaWtsotsMhkRBSp6lmQXT0zXTQLsOjxVAjUofk4RdX99HRSpleOhPAVOg==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/><\/a>Phone: 212.896.1276<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzU4YTFmNDctZTExYy00MjlhLTljOWMtOGE5NTI3ZjQxZDE5LTExMzU4OTM=\/tiny\/SELLAS-Life-Sciences-Group-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GFH009 Formulation is Near Physiological pH, While Still Achieving Desired Effect &#8211; GFH009 at pH 6.0 Decreased Potential for Infusion Reaction and Made Dosing Better Tolerated After Multiple Doses or Long-time Infusion &#8211; NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (\u201cSELLAS\u201d or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced today data from a bioequivalence study for GFH009, its potent, highly selective, clinical-stage small molecule that inhibits cyclin-dependent kinase 9 (CDK9). In the ongoing Phase 1 clinical trial of GFH009 monotherapy in patients with relapsed\/refractory hematologic conditions, including acute myeloid leukemia and lymphoma, GFH009 is administered intravenously as &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-690226","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GFH009 Formulation is Near Physiological pH, While Still Achieving Desired Effect &#8211; GFH009 at pH 6.0 Decreased Potential for Infusion Reaction and Made Dosing Better Tolerated After Multiple Doses or Long-time Infusion &#8211; NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (\u201cSELLAS\u201d or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced today data from a bioequivalence study for GFH009, its potent, highly selective, clinical-stage small molecule that inhibits cyclin-dependent kinase 9 (CDK9). In the ongoing Phase 1 clinical trial of GFH009 monotherapy in patients with relapsed\/refractory hematologic conditions, including acute myeloid leukemia and lymphoma, GFH009 is administered intravenously as &hellip; Continue reading &quot;SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T12:18:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations\",\"datePublished\":\"2022-09-29T12:18:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/\"},\"wordCount\":863,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/\",\"name\":\"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI=\",\"datePublished\":\"2022-09-29T12:18:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/","og_locale":"en_US","og_type":"article","og_title":"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations - Market Newsdesk","og_description":"GFH009 Formulation is Near Physiological pH, While Still Achieving Desired Effect &#8211; GFH009 at pH 6.0 Decreased Potential for Infusion Reaction and Made Dosing Better Tolerated After Multiple Doses or Long-time Infusion &#8211; NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (\u201cSELLAS\u201d or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced today data from a bioequivalence study for GFH009, its potent, highly selective, clinical-stage small molecule that inhibits cyclin-dependent kinase 9 (CDK9). In the ongoing Phase 1 clinical trial of GFH009 monotherapy in patients with relapsed\/refractory hematologic conditions, including acute myeloid leukemia and lymphoma, GFH009 is administered intravenously as &hellip; Continue reading \"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-29T12:18:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations","datePublished":"2022-09-29T12:18:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/"},"wordCount":863,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/","name":"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI=","datePublished":"2022-09-29T12:18:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTg3NSM1MTc4MDIwIzIxMjQzMjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-for-gfh009-formulations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=690226"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690226\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=690226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=690226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=690226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}